US FDA grants surufatinib Fast Track designation for treatment of advanced and progressive pancreatic and non-pancreatic neuroendocrine tumours (NET)

Surufatinib is being developed for patients who are unable to have surgery for these conditions. It inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor, fibroblast growth factor receptor and colony stimulating factor-1 receptor.